Ellen de Kort

78 Chapter 5 Table 2. Characteristics of included studies First author, year, country Study design Premedication Smits A, 2016, Belgium Prospective observational Propofol De Kort E, 2016, the Netherlands Prospective observational Remifentanil Avino D, 2014, Belgium Non-inferiority randomized trial SG: remifentanil CG: morphine, atropine, midazolam Baleine J, 2014, France Prospective observational Nasal midazolam Durrmeyer X, 2014, France Prospective observational Atropine, sufentanil and atracurium Thall PF, 2014, USA Not applicable Not applicable Simons S, 2013, the Netherlands Prospective observational Propofol Penido MG, 2011, Brazil Double blinded randomized trial SG: propofol, remifentanil CG: propofol, midazolam Choong K, 2010, Canada Double-blinded randomized controlled trial SG: remifentanil, atropine, placebo CG: fentanyl, atropine, succinylcholine Welzing L, 2010 Germany Prospective observational Propofol Lemyre B, 2009, Canada Prospective observational Atropine, fentanyl, succinylcholine (only in GA ≥34 weeks) Van Looy, 2008, USA Prospective observational Midazolam and fentanyl Ghanta S, 2007, Australia Randomized, open-label, controlled trial SG: propofol CG: morphine, atropine, suxamethonium Dempsey E, 2006, Ireland Prospective observational Mivacurium and fentanyl Milesi C, 2006, France Prospective observational Nitrous oxide Roberts K, 2006, USA Randomized controlled trial SG: atropine, fentanyl, mivacurium CG: atropine, fentanyl